Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Jun 29, 2026
  • participants needed
    40
  • sponsor
    Celgene
Send
Updated on 5 August 2020
See if I qualify
cancer
hormone therapy
adenocarcinoma
endocrine therapy
luteinizing hormone
gonadotropin releasing hormone
gonadotropin
testosterone
androgens
bilateral orchidectomy
abiraterone
enzalutamide
serum testosterone
antiandrogen therapy
orchiectomy
adenocarcinoma of prostate
androgen suppression
metastatic castration-resistant prostate cancer
apalutamide
darolutamide
gonadorelin
castration-resistant prostate cancer
prostate cancer
metastatic hormone refractory prostate cancer

Summary

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

Description

Study CC-94676-PCA-001 is a first-in-human dose finding study to determine the safety, tolerability, PK, PD, and preliminary efficacy of CC-94676 in subjects with mCRPC who have progressed on ADT and at least one prior secondary hormonal therapy approved for CRPC (eg, abiraterone, enzalutamide, apalutamide, or darolutamide). The dose escalation will evaluate the safety and tolerability of escalating doses of CC-94676 in mCRCP subjects to determine the MTD of CC-94676. The dose expansion will further evaluate the safety and preliminary efficacy of CC-94676 administered at or below MTD in subjects with mCRPC.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder
Age 18years - 100years
Treatment CC-94676
Clinical Study IdentifierNCT04428788
SponsorCelgene
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study
Subject is a male 18 years of age at the time of signing the informed consent form (ICF)
Subjects must have histologically or cytologically confirmed adenocarcinoma of the prostate
Subjects must have documented progressive metastatic castration-resistant prostate cancer (CRPC)
Subjects must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for CRPC (eg, abiraterone, enzalutamide, apalutamide, or darolutamide)
Subjects must have serum testosterone 50 ng/dL. Subjects must continue primary androgen deprivation with a luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) if they have not undergone bilateral orchiectomy

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment
Subject has confirmed or suspected small cell carcinoma of the prostate/neuroendocrine prostate cancer
Subject has known symptomatic brain or epidural central nervous system (CNS) or spinal metastases requiring steroids (above physiologic replacement doses) or radiation
Subject had systemic anticancer therapy or investigational treatments within 4 weeks (except treatments to maintain castrate status) or 5 half-lives prior to the first dose of CC-94676, whichever is shorter
Subject had palliative radiation, strontium-89, or radium-223 4 weeks prior to the first dose of CC-94676. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study, as long as this is not a sign of clinically significant disease progression
Subject has any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
hormone therapy
adenocarcinoma
endocrine therapy
luteinizing hormone
gonadotropin releasing hormone
gonadotropin
testosterone
androgens
bilateral orchidectomy
abiraterone
enzalutamide
serum testosterone
antiandrogen therapy
orchiectomy
adenocarcinoma of prostate
androgen suppression
metastatic castration-resistant prostate cancer
apalutamide
darolutamide
gonadorelin
castration-resistant prostate cancer
prostate cancer
metastatic hormone refractory prostate cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.